a nonsignificant trendP = 0.77
On the other hand in the bevacizumab treated group, among 9 patients on incidental treatment with β-blockers we observed a nonsignificant trend toward a worse overall survival (median OS: 18.5 vs 23.6 months, HR: 0. 89, 95% CI: 0.38–2.03, P = 0.77) (Figure 5 ).